eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2012
vol. 16
 
Share:
Share:
abstract:
Original paper

Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors

Anita Chudecka-Głaz
,
Izabella Rzepka-Górska

Wspolczesna Onkol 2012; 16 (6): 520–525
Online publish date: 2013/01/04
View full text Get citation
 
PlumX metrics:
Aim of the study: The CD30L ligand is a membrane-associated glycoprotein expressed by activated CD4+Th cells, macrophages, dendritic cells, and B lymphocytes. It binds to the CD30 receptor carried on activated and helper Th cells, inducing the immune response and apoptosis. The aim of this retrospective study was to determine the level of sCD30L in the serum of patients at diagnosis of ovarian cancer and at relapse and to assess the potential association of this ligand with selected clinico-pathologic factors.

Material and methods: We studied 69 patients with ovarian cancer allocated to two groups: A – ovarian cancer at diagnosis, B – relapse of ovarian cancer and active growth of the tumor.

Results: We found high levels of sCD30L in ovarian cancer patients. Levels at relapse (21.48 ng/ml) were significantly higher than at diagnosis (11.81 ng/ml). Poor response to first-line chemotherapy was accompanied by higher levels of sCD30L and by several other findings: resistance to platinum analogs was common, neoadjuvant chemotherapy was needed, relapse and death during two-year follow-up were frequent.

Conclusions: Our present study might initially suggest that elevated concentration of sCD30L can be an important finding prognosticating a poor prognosis and is associated with platinum resistant and refractory cases of ovarian cancer. However, studies are needed on larger groups of patients.
keywords:

ovarian cancer, apoptosis, CD30L, prognostic factor

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.